Atai Life Sciences Stock Today

ATAI Stock  USD 1.41  0.06  4.44%   

Performance

5 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Less than 15

 
High
 
Low
Low
ATAI Life is trading at 1.41 as of the 10th of November 2024. This is a 4.44 percent up since the beginning of the trading day. The stock's open price was 1.35. ATAI Life has less than a 15 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for ATAI Life Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 11th of October 2024 and ending today, the 10th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
18th of June 2021
Category
Healthcare
Classification
Health Care
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany. Atai Life operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 167.8 M outstanding shares of which 9.59 M shares are presently shorted by private and institutional investors with about 18.44 trading days to cover. More on ATAI Life Sciences

Moving against ATAI Stock

  0.48DMAC DiaMedica Therapeutics Earnings Call TomorrowPairCorr
  0.35DOMH Dominari HoldingsPairCorr

ATAI Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.0010.0011
Notably Down
Slightly volatile
Total Current Liabilities16.5 M20.1 M
Significantly Down
Slightly volatile
Non Current Liabilities Total27.6 M29 M
Notably Down
Slightly volatile
Total Assets261.1 M293.5 M
Fairly Down
Slightly volatile
Total Current Assets217 M185.6 M
Fairly Up
Slightly volatile
Debt Levels
ATAI Life can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ATAI Life's financial leverage. It provides some insight into what part of ATAI Life's total assets is financed by creditors.
Liquidity
ATAI Life Sciences currently holds 16.48 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. ATAI Life Sciences has a current ratio of 12.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ATAI Life's use of debt, we should always consider it together with its cash and equity.

Stock Based Compensation

45.31 Million
ATAI Life Sciences (ATAI) is traded on NASDAQ Exchange in USA. It is located in Wallstrasse 16, Berlin, Germany, 10179 and employs 83 people. ATAI Life is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 236.6 M. ATAI Life Sciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 167.8 M outstanding shares of which 9.59 M shares are presently shorted by private and institutional investors with about 18.44 trading days to cover. ATAI Life Sciences currently holds about 304.06 M in cash with (84.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ATAI Life Probability Of Bankruptcy
Ownership Allocation
ATAI Life Sciences secures a total of 167.8 Million outstanding shares. ATAI Life Sciences owns 9.98 % of its outstanding shares held by insiders and 27.05 % owned by institutions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check ATAI Ownership Details

ATAI Stock Institutional Holders

InstituionRecorded OnShares
Hyperion Capital Advisors Lp2024-06-30
168.4 K
Bank Of America Corp2024-06-30
125.5 K
Geode Capital Management, Llc2024-06-30
117.2 K
State Street Corp2024-06-30
81.1 K
Sg Americas Securities, Llc2024-09-30
50.3 K
Claudia M.p. Batlle, Crp (r) Llc2024-06-30
49.9 K
Royal Bank Of Canada2024-06-30
49.7 K
Sanctuary Advisors, Llc2024-06-30
48.7 K
Hpm Partners Llc2024-06-30
48 K
Morgan Stanley - Brokerage Accounts2024-06-30
5.4 M
Walleye Trading Advisors, Llc2024-06-30
2.8 M
View ATAI Life Diagnostics

ATAI Life Historical Income Statement

As of now, ATAI Life's Selling General Administrative is increasing as compared to previous years. The ATAI Life's current Cost Of Revenue is estimated to increase to about 334.9 K, while Net Interest Income is forecasted to increase to (557.6 K). View More Fundamentals

ATAI Stock Against Markets

ATAI Life Corporate Management

Ryan BarrettGeneral VPProfile
Rolando MDChief OfficerProfile
Stephen BardinAdvisorProfile
Michael RavenSenior OperationsProfile
Madison CrawfordSr AccountingProfile
Glenn ShortSenior DevelopmentProfile
Frank StegertVice ManagementProfile

Already Invested in ATAI Life Sciences?

The danger of trading ATAI Life Sciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ATAI Life is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ATAI Life. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ATAI Life Sciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ATAI Life Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ATAI Life's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atai Life Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atai Life Sciences Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ATAI Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATAI Life. If investors know ATAI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATAI Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.97)
Earnings Share
(0.36)
Revenue Per Share
0.002
Quarterly Revenue Growth
0.587
Return On Assets
(0.28)
The market value of ATAI Life Sciences is measured differently than its book value, which is the value of ATAI that is recorded on the company's balance sheet. Investors also form their own opinion of ATAI Life's value that differs from its market value or its book value, called intrinsic value, which is ATAI Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATAI Life's market value can be influenced by many factors that don't directly affect ATAI Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATAI Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if ATAI Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATAI Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.